Physicians' Academy for Cardiovascular Education

Agenda Topics ▼On-demand Online-CME Podcasts News ▼Meeting Reports Slides ▼About

ACC.22 ▼AHA 2021 ▼Covid-19 ▼Diabetes & CVD ▼ESC 2021 ▼

HoFH

Feb. 8, 2015

Share this page with your colleagues and friends:

Continue reading:

4 Things a cardiologist should know about triglycerides

Reducing triglycerides in REDUCE-IT

10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME

The spectrum of triglyceride-containing lipoproteins

10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

5 Things a cardiologist needs to know about GLP-1RA

E-learning 5 Things a cardiologist needs to know about GLP-1 RA

Online-CME - This course consists of 5 lectures.

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME

5 Things a cardiologist should know about diabetes

Slide Curriculum: Diabetes and cardiology

Slides (curriculum) - July 24, 2018

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

ACS

New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice

Agenda - Aug. 26, 2022 - Barcelona, Spain

Nearly all ACS patients reach LDL-c goal when PCSK9i is added to optimal statin therapy

Literature - June 28, 2022 - Landmesser U, et al. - Eur J Prev Cardiol. 2022

Elevated sLOX-1 levels in ACS patients predict fatal events at 1 year

Literature - May 11, 2022 - Kraler S, et al. - Eur Heart J. 2022

Atherosclerosis

CVD risk associated with LDL-c is sex specific

Literature - July 4, 2022 - Cupido AJ, et al. - J Am Heart Assoc. 2022

E-learning Inflammation: The next therapeutic frontier in targeting cardiovascular risk

Online-CME - This course consists of 4 parts.

Welcome to the EAS 2022 congress

3' education - May 24, 2022 - Prof. Kausik Ray, MD

Atrial fibrillation

E-learning Updates in anticoagulation management in AF and VTE

Online-CME - This course consists of 3 parts.

Atrial fibrillation or flutter increases risk of adverse outcomes in HFpEF

Literature - May 17, 2022 - Cikes M et al. - JACC Heart Fail. 2022

Optimizing oral anticoagulation management for patients with AF

10' education - May 3, 2022 - Prof. Robert Storey, MD

CETP inhibition

Lessons from the biology of CETP inhibition

10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD

CETP inhibitor reduces LDL-c on top of high-intensity statin

News - May 24, 2022

New oral therapy of CETP inhibition for lipid lowering

3' education - May 24, 2022 - Prof. Kausik Ray, MD

Covid-19

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 13, 2022 - Prof. Richard Hobbs, MD

2022 ACC expert consensus pathway on cardiovascular consequences of COVID-19

News - Mar. 24, 2022

Increased risk of incident CV outcomes in the post-acute phase of COVID-19

Literature - Feb. 15, 2022 - Xie Y et al. - Nat Med. 2022

CV Inflammation

E-learning Inflammation: The next therapeutic frontier in targeting cardiovascular risk

Online-CME - This course consists of 4 parts.

Need for a stratified approach to improve treatment of IHD

3' education - May 24, 2022 - Prof. Filippo Crea, MD

Elevated sLOX-1 levels in ACS patients predict fatal events at 1 year

Literature - May 11, 2022 - Kraler S, et al. - Eur Heart J. 2022

Diabetes & CVD

SGLT2i attenuates longitudinal rises in CV biomarkers in T2DM patients

Literature - July 25, 2022 - Vaduganathan M, et al. - J Am Coll Cardiol. 2022

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022

Expanding evidence on SGLT2i: Where are we now and what can we expect?

10' education - July 21, 2022 - Prof. Scott Solomon, MD

ESC Diabetes guidelines 2019

Slides: 2019 ESC guidelines on diabetes, pre-diabetes and cardiovascular diseases - Expert insights and rationale

Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

New ESC/EASD Guidelines on diabetes no longer regard metformin as first-line therapy

News - Sep. 3, 2019

ESC/EAS Guidelines dyslipidaemias 2019

LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

10' education - Oct. 4, 2019 - Prof. Brian Ference, MD

Slides: LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell

Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019

Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines

5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME

Global Heart Failure Academy education on ReachMD

Outcomes, pathophysiology and management of iron deficiency in HF

10' education - Feb. 22, 2022 - Robert Mentz, MD and prof. Peter van der Meer, MD, PhD

Potassium binders as enablers of RAASi therapy in HF

10' education - Feb. 16, 2022 - Prof. Javed Butler, MD and prof. Giuseppe Rosano, MD, PhD

Expert Insights: Managing Patients with CKD, Hyperkalemia, and Continued RAASi Therapy Through a Case Study Approach

GLP-1 RA & CVD

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD

Substantial weight loss by dual GIP and GLP-1 receptor agonist in obese individuals

Literature - June 13, 2022 - Jastreboff AM, et al. - N Engl J Med. 2022

Heart Failure

E-learning Clinical dilemmas in heart failure: Weighing the balance of RAASi and hyperkalemia

Online-CME - This course consists of 3 parts.

E-learning When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Online-CME - This course consists of 3 parts.

Intolerance to ARNI is common in advanced chronic HFrEF

Literature - July 25, 2022 - Vader JM, et al . - JACC Heart Fail. 2022

Icosapent Ethyl Resources

Final guidance by NICE in UK on recommendation for use of icosapent ethyl

News - July 19, 2022

CAC score can identify REDUCE-IT-eligible patients who benefit most from icosapent ethyl

Literature - July 18, 2022 - Mortensen MB, et al. - Eur J Prev Cardiol. 2022

New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice

Agenda - Aug. 26, 2022 - Barcelona, Spain

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Kidney disease & CVD

E-learning Rethinking the role of nephrologists in prevention of CKD – The opportunity of early risk identification

Online-CME - This course consists of 3 parts.

SGLT2i attenuates longitudinal rises in CV biomarkers in T2DM patients

Literature - July 25, 2022 - Vaduganathan M, et al. - J Am Coll Cardiol. 2022

E-learning Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

Online-CME - This course consists of 3 parts.

LDL-c Key Lessons

Key lessons on LDL-c and CV risk

LDL-c Key lessons

Screening for familial hypercholesterolemia after ACS pays off

LDL-c Key Lessons

LDL-c lowering treatment impacts disease progression before clinical manifestation

LDL-c Key Lessons

Lipids

Moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in ASCVD

Literature - Aug. 1, 2022 - Kim BK, et al. - Lancet. 2022

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD

Greater LDL-c reduction by PCSK9i in FH patients in time-averaged analysis

Literature - July 18, 2022 - Schludi B, et al. - J Clin Lipidol. 2022

Lp(a)

Lp(a): from causality to therapy

Agenda - Aug. 28, 2022 - Barcelona, Spain

No role of Lp(a) in thrombosis

3' education - June 16, 2022 - Prof. Alberico Catapano, PhD

How to overcome the excess ASCVD risk conferred by Lp(a)?

3' education - June 1, 2022 - Prof. Alberico Catapano, PhD

PCSK9

Network meta-analysis of LLTs in patients with hypercholesterolemia and high CV risk

Literature - July 28, 2022 - Burnett H, et al. - Curr Med Res Opin. 2022

Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?

10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD

Greater LDL-c reduction by PCSK9i in FH patients in time-averaged analysis

Literature - July 18, 2022 - Schludi B, et al. - J Clin Lipidol. 2022

Pulmonary Arterial Hypertension

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Low-risk profile in pulmonary arterial hypertension patients predicts better survival

Literature - June 6, 2017 - Kylhammar D, et al. - Eur Heart J 2017

SGLT2i

E-learning When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Online-CME - This course consists of 3 parts.

SGLT2i attenuates longitudinal rises in CV biomarkers in T2DM patients

Literature - July 25, 2022 - Vaduganathan M, et al. - J Am Coll Cardiol. 2022

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022

siRNA therapy and LDL-C

Network meta-analysis of LLTs in patients with hypercholesterolemia and high CV risk

Literature - July 28, 2022 - Burnett H, et al. - Curr Med Res Opin. 2022

Sustained LDL-c lowering with PCSK9 siRNA in patients with prior MI

News - Apr. 19, 2022

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD

Triglycerides

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD

Final guidance by NICE in UK on recommendation for use of icosapent ethyl

News - July 19, 2022

CAC score can identify REDUCE-IT-eligible patients who benefit most from icosapent ethyl

Literature - July 18, 2022 - Mortensen MB, et al. - Eur J Prev Cardiol. 2022

© 2006 - 2022 pace-cme.org - About